Not many biotech executives could coolly assure investors that they wouldn’t see further dilution as they stared down the barrel of bankruptcy. Just weeks from tripping over a $20 million cash threshold with its creditors, Westlake Village-based MannKind announced that it had secured a deal that would deliver a $45 million infusion of capital and…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
